<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800319</url>
  </required_header>
  <id_info>
    <org_study_id>ALK33-001</org_study_id>
    <nct_id>NCT00800319</nct_id>
  </id_info>
  <brief_title>ALK33-001: A Study of RDC-0313 Administered to Healthy Adults</brief_title>
  <official_title>ALK33-001: A Phase 1 Study of the Pharmacokinetics of RDC-0313 Administered to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of
      RDC-0313 following oral administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, double-blind, ascending dose, placebo controlled study.
      Dosing sequences will consist of 5 administrations of an oral solution of either ascending
      doses of RDC-0313 or volume-match placebo. Dosing of cohorts will be staggered to allow a
      blinded safety review to occur prior to dosing the next cohort. Subjects will be admitted to
      the facility the morning before each dose, and will be required to fast overnight prior to
      study drug administration. They will be discharged from the facility after the 36-hour
      postdose assessments are completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentrations (Cmax) of RDC-0313</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant abnormal laboratory findings</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>RDC-0313, 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg of RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDC-0313, 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg RDC-0313; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>volume-match placebo; single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDC-0313</intervention_name>
    <description>Oral solution given in 5, 15, 25, 50, and 75 mg single doses</description>
    <arm_group_label>RDC-0313, 5mg</arm_group_label>
    <arm_group_label>RDC-0313, 15 mg</arm_group_label>
    <arm_group_label>RDC-0313, 25mg</arm_group_label>
    <arm_group_label>RDC-0313, 50 mg</arm_group_label>
    <arm_group_label>RDC-0313, 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Volume matched placebo; oral solution; single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 65 years of age

          -  Body mass index of 19-30 kg/m2 at screening

          -  If subject is female and of childbearing potential, she must agree to use an
             acceptable method of contraception

          -  If subject is male, he must agree to reduce the risk of a female partner becoming
             pregnant

        Exclusion Criteria:

          -  Pregnancy and/or currently breastfeeding

          -  Clinically significant medical condition or observed abnormalities

          -  Clinically significant illness within 30 days of the first study drug administration

          -  History of opioid dependence

          -  Positive urine toxicological screen for marijuana, cocaine, amphetamines, opioids,
             barbiturates, and benzodiazepines

          -  Positive resolut for any serology test performed at screening

          -  Use of alcohol-, caffeine-, or xanthine-containing products

          -  Tobacco use within 90 days before the first study drug administration

          -  Participation in a clinical trial within 30 days before screening

          -  Requirement of a special diet other than vegetarian, or significant food allergy or
             intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip T. Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase One Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Phase One Services</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol dependence</keyword>
  <keyword>Opioid antagonist</keyword>
  <keyword>RDC-0313</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ALKS-33</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

